IN8bio Reports Q1 2026 Financial Results with $5.1 Million Net Loss

IN8bio, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $5.1 million, a slight improvement from the $5.6 million loss recorded in the same period of 2025. The company's operating expenses decreased to $5.3 million from $5.7 million year-over-year, primarily due to reduced research and development costs, which fell to $2.6 million from $3.0 million. General and administrative expenses remained relatively stable at $2.7 million. The company also reported interest income of $0.2 million, up from $0.1 million in the prior year.

As of March 31, 2026, IN8bio's total assets were $26.3 million, down from $32.3 million at the end of 2025. The decline in assets was attributed to a decrease in cash and cash equivalents, which fell to $21.9 million from $27.1 million. The company's accumulated deficit increased to $146.2 million, reflecting ongoing operational losses since its inception. Total liabilities decreased to $3.5 million from $4.7 million, primarily due to a reduction in accrued expenses and other current liabilities.

Strategically, IN8bio continues to focus on its clinical-stage biopharmaceutical operations, particularly its gamma-delta T cell product candidates for cancer and autoimmune diseases. The company is advancing its proprietary DeltEx platform, which includes product candidates such as INB-100 and INB-200, currently in clinical trials. The company has also introduced INB-600, a new T cell engager platform, which has shown promise in preclinical studies. However, the company has paused some preclinical programs due to financial market conditions and is prioritizing its pipeline to conserve capital.

Operationally, IN8bio has not yet generated any product sales and continues to rely on equity financing to fund its operations. The company has implemented cash preservation measures to extend its financial runway, as its existing cash is not expected to cover projected operating expenses for the next 12 months. Management is exploring additional capital-raising opportunities, including equity and debt offerings, as well as potential strategic collaborations. The company may also receive up to $20.1 million in additional gross proceeds from a private placement completed in December 2025, contingent on achieving certain milestones.

Looking ahead, IN8bio faces significant challenges in securing the necessary funding to continue its operations and advance its clinical programs. The company has expressed substantial doubt about its ability to continue as a going concern if additional capital is not obtained in a timely manner. As it navigates these financial uncertainties, IN8bio remains committed to its mission of developing innovative therapies for cancer and autoimmune diseases, with ongoing clinical trials expected to provide further insights into the efficacy of its product candidates.